drugset / Trial / NCT02306187

The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis

NCT02306187

Phase 1 Unknown 100 enrolled Shinshu University
RandomizedCrossoverOpen-labelTreatment

Summary

In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment. However, the bone turnover markers or the bone mineral density (BMD) are not improved in some osteoporotic patients even though they have taken BPs and alfacalcidol more than several years. In those case, the investigators better off prescribing BPs and Eldecalcitol, instead of BPs and Alfacalcitol.

Timeline

Start
2014-12
Primary completion
2022-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Eldecalcitol Small molecule 0.5 ug Oral
Subject Eldecalcitol Small molecule 0.75 ug Oral

Indications